At NINGBO INNO PHARMCHEM CO.,LTD., we are committed to advancing scientific knowledge by providing key compounds that enable groundbreaking research. Nastorazepide (Z-360) is one such compound, distinguished by its potent and selective antagonistic activity against the CCK-2 receptor. This molecular action is central to its emerging role in innovative cancer therapies, particularly in the realm of targeted drug development.

The CCK-2 receptor is a transmembrane protein that, when activated by its natural ligand gastrin, can promote cellular growth and proliferation. In many cancers, including pancreatic cancer, this receptor is overexpressed, leading to uncontrolled tumor growth. Nastorazepide functions by binding to this receptor, preventing gastrin from activating it. This blockade interrupts the oncogenic signaling pathways, thereby inhibiting cancer cell proliferation and survival. Understanding this mechanism of action is crucial for developing effective treatments.

The significance of Nastorazepide extends beyond its primary anti-proliferative effect. Its efficacy in combination with standard chemotherapy agents, such as gemcitabine, has been demonstrated in preclinical studies to enhance survival rates in pancreatic cancer models. This synergistic potential highlights Nastorazepide as a valuable agent for combination therapy, aiming to overcome treatment resistance and improve patient outcomes. Furthermore, its reported effects in inhibiting cancer metastasis and alleviating pain suggest a broader therapeutic utility that researchers are actively exploring.

NINGBO INNO PHARMCHEM CO.,LTD. plays a pivotal role in facilitating this research by supplying high-purity Nastorazepide. Our dedication to quality ensures that researchers have access to a reliable and consistent source of this vital compound, enabling them to conduct rigorous studies and drive innovation in cancer therapy. By providing the building blocks for scientific advancement, we aim to contribute to the development of more effective and targeted treatments for challenging diseases, making Nastorazepide a key component in the future of oncology.